Experience

Davis Polk advised the sole book-running manager of a $387.5 million SEC-registered offering of 5,000,000 shares of common stock of Alnylam Pharmaceuticals, Inc. Alnylam’s common stock is…

Davis Polk advised the sole initial purchaser in connection with a Rule 144A offering by The Medicines Company of $150 million aggregate principal amount of 3.50% convertible senior…

Davis Polk advised the sole book-runner in connection with the SEC-registered secondary offering of 10,835,145 shares of common stock of NeoGenomics, Inc. by the selling stockholder, GE…

Davis Polk advised Notre Dame Intermédica Participações S.A. in connection with the equity offering by Notre Dame Intermédica and by Bain Capital, the controlling shareholder of Notre Dame…

Davis Polk advised the representatives of several initial purchasers in connection with a Rule 144A offering by DexCom, Inc. of $850 million aggregate principal amount of its 0.75% senior…

Davis Polk advised the book-running manager and representative of the underwriters in connection with the initial public offering by Taiwan Liposome Company, Ltd. of American Depositary…

Davis Polk advised the joint book-running managers and representatives of the underwriters in connection with the approximately $225 million initial public offering by Orchard Therapeutics…

Davis Polk advised the underwriters and joint global coordinators in the initial public offering and listing on the Hong Kong Stock Exchange and the international offering in reliance on…

Davis Polk advised the representatives of the underwriters in connection with the $50 million initial public offering of 6,250,000 ordinary shares of Gamida Cell Ltd. The ordinary…

Davis Polk advised Laboratorios Farmacéuticos Rovi, S.A. on its Rule 144A/Regulation S follow-on offering of 5,517,241 of its ordinary shares to raise gross proceeds of approximately €80…